uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
07 déc. 2020 16h05 HE
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Long-term Clinical Benefit and...
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
04 févr. 2020 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
08 déc. 2019 16h00 HE
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for...
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
06 juil. 2019 07h00 HE
|
uniQure Inc.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
21 juin 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
03 déc. 2018 07h00 HE
|
uniQure Inc.
-- Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and a Half Years of Follow-up – -- Second Dose Cohort Demonstrated a 93% Reduction in FIX Replacement Therapy Usage During...